ADIL Adial Pharmaceuticals, Inc.
-
Adial Pharmaceuticals, Inc. Reported Earnings
Friday, August 14, 2026 · 12:00 AM ET
Adial Pharmaceuticals, Inc. (ADIL) reported a loss of $11.25 per share on revenue of $0.00 million for the second quarter ended June 2026. .
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($11.25)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—